Teva Pharmaceuticals International and mAbxience have entered into a worldwide licencing agreement to develop an anti programmed cell death protein 1 oncology biosimilar candidate. It is the second collaboration between the two entities, building on the partnership that began in April 2024. The gold standard of business intelligence.
The new global licencing agreement aims to develop an additional oncology biosimilar, reinforcing the alliance between Teva and mAbxience. By combining their expertise and resources, the companies are committed to fostering innovation and improving healthcare accessibility for patients globally. The agreement grants Teva exclusive rights for several markets, including Europe and the US.
It is in line with mAbxience’s strategy for expansion across the globe and reflects Teva’s efforts to grow its portfolio of biosimilars through strategic partnerships. Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research.
Gain competitive edge. Your download email will arrive shortly We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form Teva business development executive vice-president Angus Grant said: “This agreement not only strengthens our alliance but also highlights our shared dedication to expanding access to critical oncology treat.
